The global medicinal cannabis market is undergoing a structural shift. Regulatory reform across Europe, combined with growing clinical evidence and patient demand, is creating a multi-billion-pound opportunity that is still in its earliest stages.
Europe: The World’s Most Attractive Market
Germany legalised medicinal cannabis in 2017 with statutory health insurance reimbursement. Patient numbers grow year-on-year. Partial recreational legalisation in 2024 further normalised cannabis and expanded the addressable market.
Across the EU, the Czech Republic, Poland, Italy, France, Portugal, Malta, Luxembourg and Denmark all have active medicinal cannabis frameworks. Each new market creates incremental demand for pharmaceutical-grade, GMP-certified product.
Supply Deficit
European domestic cultivation capacity remains structurally insufficient. The continent relies heavily on imports. This creates a clear opening for low-cost, high-quality African producers with GACP-certified supply chains and a clear pathway to GMP.
Cannabis Extracts: The Premium Segment
The global cannabis concentrates and extracts market is the fastest-growing segment. Rosin, as a solventless extract, commands a significant premium due to its pharmaceutical purity profile and growing consumer preference for clean-label products.
South Africa: A Growing Market on Our Doorstep
While Europe is our primary target, one of the fastest-growing medicinal cannabis markets in the world is right on our doorstep. South Africa is home to a domestic medical cannabis market serving a population of over 60 million people and is rapidly emerging as one of the largest cannabis markets on the continent.
Lesotho, entirely surrounded by South Africa, is uniquely positioned to supply this market with minimal logistics and no cross-continental shipping. As South Africa’s regulatory framework matures and patient access expands, this represents a significant near-term revenue opportunity that complements our European export strategy.